GIP
LAB icon

Granite Investment Partners’s Standard BioTools LAB Stock Holding History

Granite Investment Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-189,669
Closed -$7.99M – 311
2015
Q1 		$7.99M Buy
189,669
+122,068
+181% +$4.83M 0.69% 50
2014
Q4 		$2.28M Buy
+67,601
New +$1.91M 0.26% 139

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Granite Investment Partners's LAB Position: Q2 2015 in Review

Granite Investment Partners sold out of Standard BioTools (LAB) in Q2 2015, closing a stake of 189,669 shares — an estimated $7.99M sold.

Granite Investment Partners first reported a position in LAB in Q4 2014 and held it in 2 quarters. The position peaked at $7.99M in Q1 2015. 107 funds tracked by Wall St. Rank hold LAB as of Q2 2015.

  • Granite Investment Partners reported no remaining Standard BioTools position as of Q2 2015 after selling out during the quarter.
  • Granite Investment Partners sold 189,669 Standard BioTools shares in Q2 2015, an estimated $7.99M.
  • Granite Investment Partners first reported a position in Standard BioTools in Q4 2014 and held it in 2 quarters.
  • Granite Investment Partners's Standard BioTools position peaked at $7.99M in Q1 2015.
  • 107 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2015.

Based on Granite Investment Partners's 13F filing for Q2 2015, filed 3 Aug 2015.